Immunotherapy research programs across Geisel have been at the forefront of efforts to mobilize the immune system to fight disease and to build the molecular platforms that have been essential to the success of new therapies. Today, our faculty are pioneering the identification of new immune system targets, creating and testing new ways of activating the immune system, and pursuing strategies to induce long-term immunity to life-threatening diseases.

New philanthropic support will fuel discovery and clinical translation within one of Geisel’s most successful and high-potential areas of innovation.

Scientists are engineering immune cells to find and kill tumor cells. Geisel immunologist Charles Sentman, PhD, and colleagues from across Dartmouth are developing CAR T-cell therapies that can potentially treat nearly 80-90% of human tumors, as explained in this video.